

# **iRGD-targeted peptide nanoparticles for anti-angiogenic RNAi-based therapy of endometriosis**

**Anna Egorova<sup>1</sup>, Mariya Petrosyan<sup>2†</sup>, Marianna Maretina<sup>1</sup>, Elena Bazian<sup>2</sup>, Iuliia Krylova<sup>3</sup>, Vladislav Baranov<sup>1†</sup> and Anton Kiselev<sup>1,\*</sup>**

<sup>1</sup> Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendelevskaya Line 3, 199034 Saint-Petersburg, Russia; A.E. egorova\_anna@yahoo.com;

<sup>2</sup> Pharmacology Group, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendelevskaya Line 3, 199034 Saint-Petersburg, Russia

<sup>3</sup> Department of Pathology, Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo Street 6-8, 197022 Saint-Petersburg, Russia

\* Correspondence: ankiselev@yahoo.co.uk


† This work is dedicated to memory of our colleagues who passed away in 2022 year

**Contents**


**Figure S1.** Silencing of GFP expression after treatment of MDA-MB-231 cells with the siRNA-complexes in presence of 10% fetal bovine serum.....3

**Figure S2.** Visual appearance of migrated EA.Hy926 cells after treatment with the siRNA complexes.....4

**Figure S3.** Monitoring of animals’ weights during experiment in vivo .....6




**Figure S1.** Silencing of GFP expression after treatment of MDA-MB-231 cells with the siRNA-complexes in presence of 10% fetal bovine serum. \* -  $p < 0.05$  when compared with cells treated by corresponding mock siRNA-complexes. The data are shown as the mean  $\pm$  S.E.M.




(a)

(b)




(c)

(d)




(e)


(f)




(g)

(h)





**Figure S2.** Visual appearance of migrated EA.Hy926 cells after treatment with **(a)** RGD1-R6/anti-VEGFA siRNA at N/P ratio 8/1 **(b)** RGD1-R6/mock siRNA at N/P ratio 8/1, **(c)** RGD1-R6/anti-VEGFA at N/P ratio 16/1, **(d)** RGD1-R6/mock siRNA at N/P ratio 16/1, **(e)** RGD0-R6/anti-VEGFA at N/P ratio 8/1, **(f)** RGD0-R6/mock siRNA at N/P ratio 8/1, **(g)** RGD0-R6/anti-VEGFA at N/P ratio 16/1, **(h)** RGD0-R6/mock siRNA at N/P ratio 16/1, **(i)** x-tremeGENE/anti-VEGFA siRNA, **(j)** x-tremeGENE/mock siRNA, **(k)** naked anti-VEGFA siRNA, **(l)** mock siRNA.



**Figure S3.** Monitoring of animals' weights during experiment in vivo.